CDK4 and breast carcinoma: Here, we assessed the efficacy of fulvestrant, CDK4/6i and AKTi as single agents and in different combinations in MCF-7 and T47D breast cancer cell lines exhibiting acquired resistance to combined CDK4/6i and fulvestrant treatment (MPF-R and TPF-R, respectively).